Fundz

Kernal Biologics Announces $25M Series A Financing To Advance Its Mrna 2.0 Technology For Oncology

PRIVATEJul 07, 2022

Amount Raised

$25 Million

Round Type

Series A

CambridgeBiotechnologyHealthcareHealth Careresearch

Description

Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients' survival rate and quality of life — today announced the completion of a $25 million Series A financing led by Hummingbird Ventures. Amgen Ventures, HBM Genomics and Civilization Ventures along with other VCs, family offices and high net worth individuals also participated in the round.

Who to call at Kernal Biologics, and when

A new round usually means Kernal Biologics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kernal Biologics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kernal Biologics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kernal Biologics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kernal Biologics

Location

700 MAIN STREET

Cambridge, Massachusetts, United States

About

Kernal Bio is a venture-backed therapeutics company engineering cells inside the body using AI-designed, selective mRNA and targeted LNP technology. By developing in vivo CAR-T therapies, Kernal Bio is advancing precision treatments for autoimmune diseases and blood cancers. The company was founded by experts from MIT, Harvard, Merck, and BMS, and its leadership team brings a track record of three FDA-approved therapies and over 120 patents. With support from leading investors — including Hummingbird Ventures, Amgen Ventures, Y Combinator, FoundersX, and HBM — Kernal Bio is transforming the future of cell therapy design and delivery.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kernal Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsYusuf E., Executive Officer, Director hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Kernal Biologics's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Kernal Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.